Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
7 enrolled 14 charts
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
Phase 2 Completed
27 enrolled 10 charts
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Phase 2 Completed
78 enrolled
FORTIFY
Phase 1 Completed
14 enrolled
Cabozantinib and Pembrolizumab in Metastatic Pancreas
Phase 2 Completed
21 enrolled 12 charts
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Phase 1/2 Completed
89 enrolled 24 charts
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Phase 1 Completed
48 enrolled
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
42 enrolled
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Completed
260 enrolled 52 charts
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Phase 1 Completed
109 enrolled
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Phase 1 Completed
185 enrolled 28 charts
SWIPE
Phase 2 Completed
48 enrolled 14 charts
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
Phase 1 Completed
72 enrolled
KEYNOTE-B84
Phase 1/2 Completed
49 enrolled
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Phase 1 Completed
518 enrolled
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Phase 2 Completed
53 enrolled 14 charts
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Phase 1 Completed
58 enrolled 17 charts
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Phase 1 Completed
52 enrolled 21 charts
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
35 enrolled
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
Phase 1 Completed
27 enrolled
Pembrolizumab in Biliary Tract Cancer
Phase 2 Completed
50 enrolled
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Phase 1 Completed
36 enrolled
ST-ICI
Completed
150 enrolled
CHEMOIMMUNE
Phase 2 Completed
36 enrolled
A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
29 enrolled
KEYNOTE-001
Phase 1 Completed
1,260 enrolled 45 charts
PANACEA
Phase 1/2 Completed
58 enrolled 16 charts